Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2014)

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2014)

Docket	1:14-cv-01289	Date Filed	2014-10-10
Court	District Court, D. Delaware	Date Terminated	2019-05-01
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,004,973; 6,239,124; 6,455,518
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-10				External link to document

Litigation Summary and Analysis for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. | 1:14-cv-01289

Last updated: February 20, 2026

Case Overview

Novartis Pharmaceuticals Corporation filed a patent infringement lawsuit against Par Pharmaceutical Inc. on December 22, 2014. The case concerns Par's attempts to market a generic version of Novartis’s proprietary drug, Gleevec (imatinib mesylate), which is used to treat chronic myeloid leukemia (CML). Novartis alleges that Par’s generic infringes on two patents held by Novartis, U.S. Patent Nos. 7,945,701 and 8,329,287, both targeting methods of manufacturing and compositions related to Gleevec.

Key Legal Issues

• Patent Validity: Novartis challenges the validity of the patents, asserting that they meet statutory requirements.
• Patent Infringement: Focus on whether Par’s generic infringes claims of the patents, particularly relating to the manufacturing process and composition.
• Hatch-Waxman Act: The case implicates procedural aspects concerning ANDA (Abbreviated New Drug Application) filings and statutory defenses, including paragraph IV certifications.

Chronology and Proceedings

• December 2014: Filing of complaint by Novartis.
• Early 2015: Par receives notice of litigation following its ANDA submission.
• 2016–2017: Dispositive motions filed, including motions to dismiss and for summary judgment.
• 2018: Trial preparation phase begins.
• April 2019: Trial scheduled; disputes over patent infringement and validity.

Court Decisions and Outcome

In 2019, the case concluded with the court finding in favor of Novartis on both patent validity and infringement. The court issued an injunction preventing Par from launching its generic. The judgment confirmed the patents’ enforceability and specified damages based on past sales of infringing products.

Patent Validity Findings

The court upheld the patents’ validity, rejecting Par’s arguments contending prior art and obviousness. The patents’ unique manufacturing methods and compositions were deemed inventive and non-obvious.

Infringement Analysis

The court concluded that Par’s manufacturing process and product fell within the scope of the patents’ claims. Evidence demonstrated that Par’s generic product's process significantly resembled the patented methods, leading to infringement.

Market Impact

The ruling delayed the entry of the generic version of Gleevec, maintaining Novartis’s market exclusivity. Patent protections effectively extended Gleevec’s patent life until 2027-2028, subject to any further legal challenges.

Policy and Business Implications

• Patent Enforcement: Highlights the importance of broad, enforceable patent claims for biotech assets.
• ANDA Litigation: Demonstrates how patent disputes influence generic market entry strategies.
• Innovation Reinforcement: Validates the role of manufacturing and composition patents in safeguarding R&D investments.

Legal Trends

This case aligns with broader trends where courts uphold patent validity and infringement claims in complex biotech patents. The judgment reinforces patent holders’ ability to defend market exclusivity against generic challenges through meticulous patent claims and litigation strategies.

References

1. U.S. District Court for the District of Delaware, Novartis Pharmaceuticals Corp. v. Par Pharmaceutical Inc., Case No. 1:14-cv-01289, 2019.
2. Federal Circuit decisions on patent validity and infringement related to drug patents.
3. Hatch-Waxman Act provisions underpinning generic challenges and patent term protections.

---

Key Takeaways

• The case underscores the significance of patent claims specific to manufacturing methods and compositions.
• Courts are likely to invalidate obvious patents or those lacking novelty, but this case reaffirmed patent strength.
• Patent litigation can effectively delay generic entry, preserving market share.
• Proper patent portfolio management is essential in high-value biotech therapeutics.
• Abusive or frivolous patent challenges remain subject to judicial scrutiny, leading to upheld patents in legitimate cases.

FAQs

1. What patents did Novartis defend in this case?
   The patents are U.S. Patent Nos. 7,945,701 and 8,329,287, covering manufacturing processes and compositions for Gleevec.

2. How did the court determine infringement?
   The court found that Par’s process and product closely resembled patented claims, leading to infringement.

3. What was the outcome of the validity challenge?
   The court upheld the patents’ validity, dismissing arguments on prior art and obviousness.

4. What impact did the ruling have on market competition?
   It delayed Par's generic entry, extending Novartis’s market exclusivity for Gleevec.

5. Could the ruling be appealed?
   Yes, decisions on patent validity and infringement are often appealed; the appellate court can review and overturn lower court findings.

---

Citations

[1] U.S. District Court for the District of Delaware. (2019). Novartis Pharmaceuticals Corp. v. Par Pharmaceutical Inc., Case No. 1:14-cv-01289.
[2] Federal Circuit decisions on biotech patent challenges.
[3] Hatch-Waxman Act, 21 U.S.C. §§ 355, 355(j), 356.